-
April 17, 2013
The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is ...
-
February 14, 2013
Charles River Laboratories (CRL) reported fourth quarter 2012 earnings (excluding special items) of 64 cents per ...
-
February 11, 2013
Leading well-being enhancement company Healthways (HWAY) and Carondelet Health Network recently revealed an ...
-
January 28, 2013
Covance Inc. (CVD) reported earnings per share (EPS) of 61 cents in the fourth quarter of 2012, higher than the ...
-
January 03, 2013
PAREXEL International Corporation (PRXL), a provider of biopharmaceutical services, recently acquired all the ...
-
January 03, 2013
Following the success of the Culex Automated in vivo sampling system, recently, pharmaceutical development company, ...
-
December 28, 2012
Paraxel International Corporation (PRXL), a provider of biopharmaceutical services, recently acquired all the ...
-
November 07, 2012
Covance (CVD) reported earnings per share (EPS) of 69 cents per share in the third quarter of 2012, up from the ...
-
November 06, 2012
The Nasdaq remains relatively unchanged, the S&P 500 has climbed 0.4% and the Dow is trading up 0.6% so far today. ...
-
September 21, 2012
Parexel International Corporation (PRXL), a leading provider of biopharmaceutical services, recently announced that ...
-
August 29, 2012
Currently, the Nasdaq has decreased 0.2%, the S&P 500 has been relatively flat and the Dow has remained steady. The ...
-
August 10, 2012
The board of Parexel International Corporation (PRXL), leading provider of biopharmaceutical services, recently ...
-
July 26, 2012
Leading provider of biopharmaceutical services, Parexel International Corporation (PRXL) recently announced the ...
-
July 26, 2012
Covance (CVD) reported a loss of 23 cents per share in the second quarter of 2012, deteriorating significantly from ...
-
October 06, 2011
PPD's acceptance of a low buyout bid raises questions about the CRO industry.
-
July 28, 2011
LabCorp's valuation is quite reasonable but cash flow growth remains an issue.
-
March 02, 2011
Icon still has a stellar growth track record and industry trends suggest there could be much growth for the company.
-
July 06, 2010
Investors looking to play the growth in R&D spending for human drugs should consider CROs.
-
August 15, 2008
Contract research organizations are an unexplored niche of the healthcare sector. As a whole, they've reported ...
-
October 01, 2007
We examine three companies that the big drug makers call on when they need a little testing done.
